HK1208232A1 - Gip-glp-1 dual agonist compounds and methods gip-glp-1 - Google Patents
Gip-glp-1 dual agonist compounds and methods gip-glp-1Info
- Publication number
- HK1208232A1 HK1208232A1 HK15108788.2A HK15108788A HK1208232A1 HK 1208232 A1 HK1208232 A1 HK 1208232A1 HK 15108788 A HK15108788 A HK 15108788A HK 1208232 A1 HK1208232 A1 HK 1208232A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gip
- glp
- methods
- agonist compounds
- dual agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261642439P | 2012-05-03 | 2012-05-03 | |
US201361765561P | 2013-02-15 | 2013-02-15 | |
PCT/EP2013/059319 WO2013164483A1 (en) | 2012-05-03 | 2013-05-03 | Gip-glp-1 dual agonist compounds and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1208232A1 true HK1208232A1 (en) | 2016-02-26 |
Family
ID=48325702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108788.2A HK1208232A1 (en) | 2012-05-03 | 2015-09-09 | Gip-glp-1 dual agonist compounds and methods gip-glp-1 |
Country Status (20)
Country | Link |
---|---|
US (2) | US10100097B2 (hu) |
EP (1) | EP2844669B1 (hu) |
JP (1) | JP6228187B2 (hu) |
KR (1) | KR102184241B1 (hu) |
CN (1) | CN104470948B (hu) |
AR (1) | AR090937A1 (hu) |
AU (1) | AU2013255751B2 (hu) |
BR (1) | BR112014027348B1 (hu) |
CA (1) | CA2872314C (hu) |
EA (1) | EA028665B1 (hu) |
HK (1) | HK1208232A1 (hu) |
IL (1) | IL235463A0 (hu) |
IN (1) | IN2014MN02304A (hu) |
MX (1) | MX356641B (hu) |
NZ (1) | NZ702333A (hu) |
PH (1) | PH12014502452A1 (hu) |
SG (1) | SG11201407137PA (hu) |
TR (1) | TR201815338T4 (hu) |
TW (1) | TWI689515B (hu) |
WO (1) | WO2013164483A1 (hu) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
CN104470948B (zh) | 2012-05-03 | 2018-06-15 | 西兰制药公司 | Gip-glp-1双激动剂化合物及方法 |
CA2878991C (en) | 2012-07-23 | 2021-12-07 | Zealand Pharma A/S | Glucagon analogues |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
JP2016503046A (ja) * | 2012-12-19 | 2016-02-01 | ノヴォ ノルディスク アー/エス | コレステロール流出活性を有する新規glp−1受容体アゴニスト |
JP2016503771A (ja) | 2012-12-21 | 2016-02-08 | サノフイ | エキセンジン−4誘導体 |
ES2900744T3 (es) | 2013-05-28 | 2022-03-18 | Takeda Pharmaceuticals Co | Compuesto de péptidos |
AR098065A1 (es) | 2013-10-17 | 2016-04-27 | Zealand Pharma As | Análogos de glucagón acilados |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
WO2015067715A2 (en) * | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
WO2015081891A1 (en) | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
EP3985016A1 (en) | 2014-10-29 | 2022-04-20 | Zealand Pharma A/S | Gip agonist compounds and methods |
JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
KR20170137198A (ko) | 2015-04-16 | 2017-12-12 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
JP2018529749A (ja) | 2015-10-07 | 2018-10-11 | シプルメット・ゲーエムベーハー | ペプチド薬物を経口送達するための医薬製剤 |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
US10501516B2 (en) | 2016-05-24 | 2019-12-10 | Takeda Pharmaceutical Company Limited | Peptide compound |
WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
WO2019140030A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
US10577905B2 (en) | 2018-02-12 | 2020-03-03 | Eagle Technology, Llc | Hydrocarbon resource recovery system and RF antenna assembly with latching inner conductor and related methods |
WO2019193204A1 (en) | 2018-04-06 | 2019-10-10 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
EP3788063B1 (en) | 2018-05-04 | 2023-08-09 | Novo Nordisk A/S | Gip derivatives and uses thereof |
US11084861B2 (en) * | 2018-07-23 | 2021-08-10 | Eli Lilly And Company | GIP/GLP1 co-agonist compounds |
IL308674A (en) | 2018-07-23 | 2024-01-01 | Lilly Co Eli | Methods of using a GIP/GLP1 co-agonist for diabetes |
WO2020067557A2 (en) * | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
AU2020206388B2 (en) * | 2019-01-07 | 2022-12-01 | Vitalixir (Beijing) Co., Ltd | Novel polypeptide and therapeutic uses thereof |
WO2020207477A1 (zh) * | 2019-04-11 | 2020-10-15 | 江苏豪森药业集团有限公司 | Glp-1和gip受体双重激动剂化合物及其应用 |
AR119471A1 (es) | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
WO2021034815A1 (en) | 2019-08-19 | 2021-02-25 | Eli Lilly And Company | Methods of making incretin analogs |
WO2021066600A1 (ko) | 2019-10-04 | 2021-04-08 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
AU2020384729A1 (en) | 2019-11-11 | 2022-04-14 | Boehringer Ingelheim International Gmbh | NPY2 receptor agonists |
CN113383014B (zh) * | 2019-11-15 | 2024-06-18 | 江苏豪森药业集团有限公司 | 双受体重激动剂化合物及其药物组合物 |
TWI770781B (zh) * | 2020-01-23 | 2022-07-11 | 美商美國禮來大藥廠 | Gip/glp1共促效劑化合物 |
TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型glp-1/gip雙重促效劑 |
BR112023000229A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
JP2023534131A (ja) | 2020-07-22 | 2023-08-08 | ノヴォ ノルディスク アー/エス | 経口送達に好適なglp-1受容体およびgip受容体共作動薬 |
CA3185637A1 (en) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Soluble npy2 receptor agonists |
EP4210680A1 (en) | 2020-09-07 | 2023-07-19 | Cyprumed GmbH | Improved pharmaceutical formulations of glp-1 receptor agonists |
TW202229323A (zh) | 2020-10-17 | 2022-08-01 | 印度商太陽製藥工業有限公司 | 新型glp-1/gip雙重促效劑 |
WO2022117056A1 (zh) * | 2020-12-02 | 2022-06-09 | 南京明德新药研发有限公司 | 含内酰胺修饰的多肽类化合物 |
CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
JP2023552500A (ja) * | 2020-12-23 | 2023-12-15 | 浙江道尓生物科技有限公司 | 長時間作用型グルカゴン誘導体 |
WO2022235991A1 (en) | 2021-05-07 | 2022-11-10 | Eli Lilly And Company | Erodible tablet |
CN117440964A (zh) * | 2021-06-01 | 2024-01-23 | 南京知和医药科技有限公司 | 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途 |
WO2023030444A1 (zh) * | 2021-09-02 | 2023-03-09 | 广东东阳光药业有限公司 | Glp-1/gip双靶多肽、融合蛋白及其应用 |
CN118103391A (zh) * | 2021-11-12 | 2024-05-28 | 福建盛迪医药有限公司 | Glp-1受体和gip受体双重激动剂的药物组合物及其用途 |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
WO2024015922A2 (en) * | 2022-07-15 | 2024-01-18 | Pep2Tango Therapeutics Inc. | Compositions including multi-agonist peptides and methods of manufacture and use |
WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
WO2024059674A1 (en) | 2022-09-15 | 2024-03-21 | Eli Lilly And Company | Gip and glp-1 dual agonist compounds |
CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
PT944648E (pt) | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
NZ334595A (en) | 1996-09-09 | 2000-08-25 | Zealand Pharmaceuticals As | Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage |
DE69732640T2 (de) | 1996-09-09 | 2006-01-12 | Zealand Pharma A/S | Festphasen-peptidsynthese |
MXPA00004670A (es) | 1997-11-14 | 2003-07-14 | Amylin Pharmaceuticals Inc | Compuestos agonistas de exendina novedosos. |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
BR9915961A (pt) | 1998-12-07 | 2001-08-21 | Sod Conseils Rech Applic | Análogos de glp-1 |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
BR0009040A (pt) | 1999-03-17 | 2001-12-18 | Novo Nordisk As | Método para acilar um grupo amino de um peptìdeoou de uma proteìna, e, composto |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
WO2003053460A1 (en) | 2001-12-19 | 2003-07-03 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
WO2003053339A2 (en) | 2001-12-20 | 2003-07-03 | Eli Lilly And Company | Insulin molecule having protracted time action |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
KR20050121748A (ko) | 2003-04-29 | 2005-12-27 | 일라이 릴리 앤드 캄파니 | 연장된 시간 작용을 갖는 인슐린 유사체 |
CA2586771A1 (en) | 2004-11-12 | 2006-05-18 | Novo Nordisk A/S | Stable formulations of insulinotropic peptides |
CN101155828A (zh) * | 2005-02-11 | 2008-04-02 | 安米林药品公司 | Gip类似物和具有可选择性质的杂合多肽 |
TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
JP2008539735A (ja) * | 2005-05-06 | 2008-11-20 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | グルカゴン様ペプチド1(glp−1)受容体アンタゴニストおよびそれらの薬理学的使用方法 |
KR101349808B1 (ko) | 2005-06-13 | 2014-02-13 | 임페리얼 이노베이션스 리미티드 | 섭취행동에 관한 신규 화합물들 및 이들의 효능 |
WO2007024899A2 (en) | 2005-08-23 | 2007-03-01 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
WO2007056362A2 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
CN101389648B (zh) | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
CN101432025B (zh) * | 2006-03-21 | 2012-04-04 | 安米林药品公司 | 肽-肽酶抑制剂结合物及其使用方法 |
AU2007274738B2 (en) | 2006-07-18 | 2013-11-28 | Sanofi-Aventis | Antagonist antibody against EphA2 for the treatment of cancer |
ITMI20061607A1 (it) | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
EP2057189B1 (en) * | 2006-08-25 | 2013-03-06 | Novo Nordisk A/S | Acylated exendin-4 compounds |
ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
EP2111414B1 (en) | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
JP5547083B2 (ja) | 2007-11-20 | 2014-07-09 | アンブルックス,インコーポレイテッド | 修飾されたインスリンポリペプチドおよびそれらの使用 |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
AU2009203810B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
DK2229407T3 (en) | 2008-01-09 | 2017-02-27 | Sanofi Aventis Deutschland | NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE |
DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
WO2009129250A2 (en) | 2008-04-14 | 2009-10-22 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
KR20110021758A (ko) | 2008-04-22 | 2011-03-04 | 케이스 웨스턴 리저브 유니버시티 | 이형체-특이적 인슐린 유사체 |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 pH 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
EA019203B9 (ru) | 2008-06-17 | 2014-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты глюкагонового рецептора/glp-1-рецептора |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
KR20110061552A (ko) | 2008-07-31 | 2011-06-09 | 케이스 웨스턴 리저브 유니버시티 | 할로겐 안정화된 인슐린 |
AU2009280017B2 (en) * | 2008-08-07 | 2013-01-10 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
CN102149411A (zh) | 2008-09-12 | 2011-08-10 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
EA020537B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
US8680049B2 (en) | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
EP2370461B1 (en) | 2008-12-15 | 2013-10-02 | Zealand Pharma A/S | Glucagon analogues |
AU2008365556A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
WO2010107487A2 (en) | 2009-03-18 | 2010-09-23 | Wu Nian | Lipid-drug conjugates for drug delivery |
CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
WO2011080102A2 (en) | 2009-12-16 | 2011-07-07 | Novo Nordisk A/S | Glp-1 analogues and derivatives |
NZ601167A (en) | 2010-01-20 | 2014-12-24 | Zealand Pharma As | Treatment of cardiac conditions |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
US20130053310A1 (en) | 2010-03-26 | 2013-02-28 | Novo Nordisk A/S | Novel glucagon analogues |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
EP2565205B1 (en) | 2010-04-27 | 2015-07-01 | Betta Pharmaceuticals Co., Ltd. | Glucagon-like peptide-1 analogue and use thereof |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
EA201291234A1 (ru) | 2010-06-24 | 2013-07-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
US9006178B2 (en) | 2010-11-09 | 2015-04-14 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives with a linker |
BR112013018269A2 (pt) | 2011-01-20 | 2017-06-06 | Zealand Pharma As | combinação de análogos acilados do glucagon com análogos da insulina |
JP2014510739A (ja) | 2011-03-28 | 2014-05-01 | ノヴォ ノルディスク アー/エス | 新規のグルカゴン類似体 |
PT2696687T (pt) | 2011-04-12 | 2017-02-02 | Novo Nordisk As | Derivados de glp-1 duplamente acilados |
WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
JP5914641B2 (ja) * | 2011-06-10 | 2016-05-11 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドBeijing Hanmi Pharmaceutical Co., Ltd. | グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用 |
EP2758426B1 (en) | 2011-09-23 | 2019-08-07 | Novo Nordisk A/S | Novel glucagon analogues |
MX2014007120A (es) | 2011-12-23 | 2015-03-05 | Boehringer Ingelheim Int | Analogos de glucagon. |
CN104470948B (zh) | 2012-05-03 | 2018-06-15 | 西兰制药公司 | Gip-glp-1双激动剂化合物及方法 |
CA2878991C (en) | 2012-07-23 | 2021-12-07 | Zealand Pharma A/S | Glucagon analogues |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
AR098065A1 (es) | 2013-10-17 | 2016-04-27 | Zealand Pharma As | Análogos de glucagón acilados |
WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
RU2016134425A (ru) | 2014-02-18 | 2018-03-20 | Ново Нордиск А/С | Стабильные аналоги глюкагона и их применение для лечения гипогликемии |
KR20170137198A (ko) | 2015-04-16 | 2017-12-12 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
-
2013
- 2013-05-03 CN CN201380032714.4A patent/CN104470948B/zh active Active
- 2013-05-03 IN IN2304MUN2014 patent/IN2014MN02304A/en unknown
- 2013-05-03 KR KR1020147033952A patent/KR102184241B1/ko active IP Right Grant
- 2013-05-03 EA EA201491918A patent/EA028665B1/ru not_active IP Right Cessation
- 2013-05-03 US US14/398,260 patent/US10100097B2/en active Active
- 2013-05-03 TW TW102115949A patent/TWI689515B/zh active
- 2013-05-03 MX MX2014013318A patent/MX356641B/es active IP Right Grant
- 2013-05-03 AR ARP130101524A patent/AR090937A1/es unknown
- 2013-05-03 EP EP13720931.8A patent/EP2844669B1/en active Active
- 2013-05-03 TR TR2018/15338T patent/TR201815338T4/tr unknown
- 2013-05-03 SG SG11201407137PA patent/SG11201407137PA/en unknown
- 2013-05-03 AU AU2013255751A patent/AU2013255751B2/en active Active
- 2013-05-03 WO PCT/EP2013/059319 patent/WO2013164483A1/en active Application Filing
- 2013-05-03 BR BR112014027348-0A patent/BR112014027348B1/pt active IP Right Grant
- 2013-05-03 CA CA2872314A patent/CA2872314C/en active Active
- 2013-05-03 NZ NZ702333A patent/NZ702333A/en unknown
- 2013-05-03 JP JP2015509461A patent/JP6228187B2/ja active Active
-
2014
- 2014-11-02 IL IL235463A patent/IL235463A0/en unknown
- 2014-11-03 PH PH12014502452A patent/PH12014502452A1/en unknown
-
2015
- 2015-09-09 HK HK15108788.2A patent/HK1208232A1/xx unknown
-
2018
- 2018-09-05 US US16/121,745 patent/US20190135886A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2015517459A (ja) | 2015-06-22 |
PH12014502452A1 (en) | 2015-02-02 |
AR090937A1 (es) | 2014-12-17 |
CA2872314C (en) | 2021-08-31 |
BR112014027348A2 (pt) | 2017-06-27 |
TWI689515B (zh) | 2020-04-01 |
TW201348252A (zh) | 2013-12-01 |
EP2844669A1 (en) | 2015-03-11 |
US20190135886A1 (en) | 2019-05-09 |
IN2014MN02304A (hu) | 2015-08-07 |
KR20150003910A (ko) | 2015-01-09 |
US10100097B2 (en) | 2018-10-16 |
EP2844669B1 (en) | 2018-08-01 |
EA201491918A1 (ru) | 2015-07-30 |
CN104470948A (zh) | 2015-03-25 |
BR112014027348B1 (pt) | 2022-12-20 |
AU2013255751A1 (en) | 2014-12-18 |
CA2872314A1 (en) | 2013-11-07 |
EA028665B1 (ru) | 2017-12-29 |
KR102184241B1 (ko) | 2020-12-01 |
NZ702333A (en) | 2017-06-30 |
WO2013164483A1 (en) | 2013-11-07 |
IL235463A0 (en) | 2014-12-31 |
TR201815338T4 (tr) | 2018-11-21 |
MX356641B (es) | 2018-06-07 |
MX2014013318A (es) | 2015-09-28 |
US20150299281A1 (en) | 2015-10-22 |
AU2013255751B2 (en) | 2017-10-05 |
CN104470948B (zh) | 2018-06-15 |
JP6228187B2 (ja) | 2017-11-08 |
SG11201407137PA (en) | 2014-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1208232A1 (en) | Gip-glp-1 dual agonist compounds and methods gip-glp-1 | |
HK1250690A1 (zh) | 方法 | |
HK1208363A1 (en) | New methods | |
HK1201200A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
EP2736330A4 (en) | COMPOUNDS AND METHODS | |
IL237309A0 (en) | Benzocyclooctyne compounds and uses thereof | |
HK1200830A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
EP2747560A4 (en) | CONNECTIONS AND METHODS | |
EP2736332A4 (en) | CONNECTIONS AND METHODS | |
EP2736329A4 (en) | COMPOUNDS AND METHODS | |
EP2850077A4 (en) | BIOZIDE COMPOUNDS AND METHOD FOR USE THEREOF | |
HK1206724A1 (en) | Substituted benzothienopyrimidines | |
EP2934541A4 (en) | NORIBOGAINE SUBSTITUTE | |
GB2507760B (en) | Methods | |
EP2842553A4 (en) | ANALGESIC | |
HK1206022A1 (zh) | 取代的咪唑並噠嗪 | |
GB201208874D0 (en) | Methods | |
PL2882708T3 (pl) | Nowe związki i ich zastosowania | |
GB201204280D0 (en) | Methods | |
GB201116152D0 (en) | Cannabinoid-2-receptor agonists | |
GB201208756D0 (en) | Methods | |
GB201216854D0 (en) | Agonist | |
GB201207075D0 (en) | New compounds and uses | |
GB201206973D0 (en) | New compounds and uses | |
GB201206055D0 (en) | New compounds and uses |